Angiotensin II plays an important role in maintaining blood pressure in postmenopausal women receiving hormone replacement therapy

What Was Tested

Researchers studied Angiotensin II in the context of low blood pressure and orthostatic hypotension in this controlled clinical trial publication.

Who Took Part

According to the abstract, 13 women were involved.

By PubMed's age tags, the people studied were middle-aged adults, women only.

How the Study Was Run

Both BP and heart rate (HR) were measured at baseline and at 1, 2, 3, 4, 5, and 6 h after administration.

Plasma renin activity (PRA) and Ang I, Ang II, and bradykinin concentrations were measured at baseline and 4 h after the administration of candesartan.

What Was Measured

Topics PubMed links to this paper include Aldosterone, Angiotensin I, Angiotensin II, Angiotensin II Type 1 Receptor Blockers, Antihypertensive Agents, Benzimidazoles and Biomarkers.

What This Means in Plain Language

This is a controlled clinical trial of Angiotensin II in 13 women in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (American journal of hypertension), a journal based in United States.

More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.